Aravive, Inc. (ARAV) financial statements (2020 and earlier)

Company profile

Business Address RIVER OAKS TOWER
HOUSTON, TX 77098
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments655781201182171
Cash and cash equivalents655781201182171
Receivables31    
Prepaid expense100322
Other undisclosed current assets000110
Total current assets:685882205185173
Noncurrent Assets
Operating lease, right-of-use asset9
Property, plant and equipment201001
Intangible assets, net (including goodwill)00    
Intangible assets, net (excluding goodwill)00    
Other noncurrent assets10  01
Other undisclosed noncurrent assets21111   
Total noncurrent assets:141112011
TOTAL ASSETS:826994206185174
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3261599
Accounts payable102121
Accrued liabilities1141376
Employee-related liabilities     2
Taxes payable   0  
Debt2     
Deferred revenue and credits 40  
Other undisclosed current liabilities 0   (2)
Total current liabilities:5265597
Noncurrent Liabilities
Long-term debt and lease obligation8     
Operating lease, liability8
Other undisclosed noncurrent liabilities085   
Total noncurrent liabilities:885   
Total liabilities:1310115597
Stockholders' equity
Stockholders' equity attributable to parent, including:696083151177167
Common stock000000
Additional paid in capital539511457441370279
Accumulated other comprehensive loss   (0)  
Accumulated deficit(470)(451)(374)(289)(193) 
Other undisclosed stockholders' equity attributable to parent     (111)
Total stockholders' equity:696083151177167
TOTAL LIABILITIES AND EQUITY:826994206185174

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net40   
Gross profit:5140   
Operating expenses(27)(77)(124)(96)(83)(46)
Operating loss:(22)(75)(84)(96)(83)(46)
Nonoperating income (expense)42(1)10(11)
Investment income, nonoperating111100
Other nonoperating income (expense)31(2)00(12)
Interest and debt expense (2)    
Loss from continuing operations before income taxes:(18)(76)(85)(96)(82)(58)
Income tax expense (benefit)  0(0)  
Net loss attributable to parent:(18)(76)(85)(96)(82)(58)
Preferred stock dividends and other adjustments     (26)
Net loss available to common stockholders, diluted:(18)(76)(85)(96)(82)(83)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(18)(76)(85)(96)(82)(58)
Comprehensive loss:(18)(76)(85)(96)(82)(58)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  0(0)  
Comprehensive loss, net of tax, attributable to parent:(18)(76)(85)(96)(82)(58)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: